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(no CSF leak; CSF leak; death). The effectiveness outcome measure was a utility index 
given to each state based on the hypothesis that utility was 1 for “no CSF leak”; 0.5 
for “CSF leak” and 0 for “death”. RESULTS: When hydrogel was used, the probabili-
ties were for no CSF leak 1.000 at T0; 0.936 at T1 and 0.876 at T2; for CSF leak 
0.000 at T0; 0.043 at T1 and 0.082 at T2; and for death 0.000 at T0; 0.021 at T1 
and 0.042 at T2. When no hydrogel was used, the probabilities were for no CSF leak 
0.060 at T0; 0.876 at T1; 0.767 at T2; for CSF leak 0.940 at T0; 0.103 at T1 and 
0.191 at T2; and for death 0.000 at T0; 0.021 at T1 and 0.042 at T2. The cost-
 effectiveness ratio was a4,720.20 at T0; a5,174.29 at T1 and a5,645.06 at T2 
when hydrogel was used and it was a27,693.48 at T0; a14,251.71 at T1 and 
a12,638.00 at T2 when hydrogel was not used. The ICER, which represents 
the additional cost necessary to gain one additional utility unit, was a9857.12. 
 CONCLUSIONS: The strategy with hydrogel was more cost-effective than the 
strategy without hydrogel.
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OBJECTIVES: Sugammadex (SGX) is a modiﬁed G-cyclodextrin that has been recently 
marketed in Spain for the reversal of neuromuscular block induced by rocuronium 
(ROC) and vecuronium. The objective of this study was to evaluate the cost-
 effectiveness of sugammadex in the management of patients with unanticipated 
 difﬁcult intubation and patients needing rapid sequence intubation from the Spanish 
National Health System perspective. METHODS: Two decision-analytic models were 
developed to assess the average per patient treatment costs (a2009), life-years gained, 
and incremental cost per life-year gained of ROC  SGX vs. succinylcholine in patients 
needing rapid sequence intubation and ROC SGX vs. all other neuromuscular block-
ing agents in the management of the unanticipated difﬁcult intubation patients. The 
models simulate the probability of not being able to intubate, the probability of 
experiencing an adverse effect, and the direct costs produced by each treatment alter-
native. Clinical data was obtained from the SmPC of each drug and form secondary 
sources. Costs were obtained for Soikos database. All data was validated by a focus 
group in order to adapt the model to the Spanish clinical practice. RESULTS: In the 
management of unanticipated difﬁcult intubation patients, ROCSGX is associated 
with higher life years gained and less costs than the intubation with atracurium or 
cisatracurium and with a mean cost per life year gained (LYG) of a11,077 vs. succi-
nylcholine based regimens. In the rapid sequence intubation model, ROCSGX is 
associated with mean expected costs of a58.11 and mean expected life years of 20.38, 
and succinylcholine with a57.89 and 20,37, meaning a cost per LYG of ROCSGX 
vs succinylcholine of a3106. CONCLUSIONS: Under the established assumptions, 
sugammadex would be a cost-effective alternative for the reversal of patients with 
unanticipated difﬁcult intubation or for the management of patients undergoing rapid 
sequence intubation.
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OBJECTIVES: To assess the cost-effectiveness of sugammadex for reversal of neuro-
muscular blockade (NMB) in Portuguese hospitals, using a clinical decision model. 
METHODS: We compared sugammadex 2.0 mg/kg with neostigmine 50 Mg/kg plus 
atropine 0.375 mg. Clinical efﬁcacy and safety data were obtained from both pub-
lished literature and phase III randomized clinical trial supporting the need for routine 
reversal of rocuronium or vecuronium NMB. Clinical events considered were drug 
adverse reactions and post-operative residual curarization. Risk of death within hos-
pitalization, duration and cost of hospitalization were estimated from hospitalizations 
in Portuguese public hospitals during 2007, with at least one surgical procedure. Only 
direct costs were considered (drugs, medical visits, side effect treatments and monitor-
ing). Effectiveness was measured in life years (LY). Premature death accounted to LY 
as the loss of remaining lifespan. Monte Carlo simulations were used to assess second-
order uncertainty. RESULTS: NMB reversal with sugammadex was estimated to result 
in a per patient gain of 2.25 LY (95%CI [1.78; 2.74]) and a decrease of a1509 (95%CI 
[-6,148; 738]) on total cost when compared to the neostigmine-atropine alternative, 
being on average a dominant strategy. Probabilistic sensitivity analysis revealed 82.6% 
probability of sugammadex dominance and 100% of being cost-effective at a thresh-
old of a1000. CONCLUSIONS: Neuromuscular blockade reversal with sugammadex 
may be considered a cost-effective strategy in comparison to neostigmine-atropine.
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OBJECTIVES: We examined whether rasagiline, a once-daily irreversible monoamine 
oxidase type-B inhibitor indicated for treatment of early Parkinson’s disease, is a 
cost-effective ﬁrst-line treatment strategy when compared with ropinirole XL, prami-
pexole, generic ropinirole, and ﬁrst-line levodopa. METHODS: We developed a 5-year 
Markov model to examine the cost-effectiveness of initiating early treatment of PD 
with rasagiline from a United States payer perspective. Comparator strategies included 
initiating therapy with ropinirole XL, pramipexole, generic ropinirole, or levodopa. 
Rasagiline was followed by either a dopamine agonist (DA) or levodopa. DA was 
followed by levodopa. Patients on a DA or levodopa could develop dyskinesias. Health 
state transitions occurred every 6 months. Transition probabilities were from clinical 
trial data. Drug costs, medical costs and utility weights were from published sources. 
One-way and probabilistic sensitivity analyses were performed. Costs and outcomes 
were discounted at 3% per year. RESULTS: Over 5 years, ﬁrst-line treatment with 
rasagiline was cost saving and more effective when compared to branded DAs and 
levodopa. Rasagiline was cost-effective versus generic ropinirole at $1,838 per quality-
adjusted life-year (QALY): incremental costs $239 and incremental QALYs 0.13. 
After ﬁve years compared to a DA, 23% and 50% fewer patients who initiated treat-
ment with rasagiline were taking levodopa and experiencing dyskinesias respectively. 
Compared to ﬁrst-line levodopa, 52% and 69% fewer patients starting rasagiline were 
taking levodopa and experiencing dyskinesias respectively. CONCLUSIONS: Initiat-
ing early Parkinson’s disease therapy with rasagiline delayed treatment with levodopa, 
reduced dyskinesias, and appears to be cost-savings or cost-effective when compared 
to initiating therapy with other ﬁrst-line therapies.
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OBJECTIVES: The societal costs of caring for patients with Alzheimer’s disease 
(AD) are substantial. In light of increasing AD prevalence, there is a need for efﬁcient 
allocation of available resources and despite few therapeutic alternatives the cost-
effectiveness of treatment with cholinesterase inhibitors has been the issue of much 
debate. The objective of this study was to use recently collected data on costs and 
utilities at different stages of AD to estimate the cost-effectiveness of donepezil com-
pared to placebo in mild-to-moderate AD in Sweden. METHODS: A twelve state 
Markov-model was developed, incorporating cognitive function (mild/moderate/
severe), ADL-dependency (independent/dependent) and care setting (home/institution). 
Data on efﬁcacy and disease progression were based on a 1-year clinical trial in 
Northern Europe and costs and utilities were based on a recently conducted cost-of-
illness study in Sweden. The cohort was simulated over ﬁve years in 6-month cycles. 
Patients were assumed to receive treatment during one year, and after that disease 
progression rates were assumed to be identical in the donepezil and the placebo group. 
RESULTS: In base case scenario, the treatment cost of donepezil (11,023 SEK) was 
offset by lower other costs of care (17,618 SEK), resulting in an overall cost-saving 
of 6595 SEK per patient compared to placebo. Donepezil treatment also delayed pro-
gression into severe AD, ADL-dependence and institutionalization and led to a gain 
of 0.056 quality-adjusted life-years (QALY). Sensitivity analyses were carried to 
analyze the impact of extending the period under which treatment costs were incurred 
and by altering the baseline characteristics. Donepezil was cost-saving in most of these 
alternative scenarios and cost-effective in all of them. CONCLUSIONS: Using new 
data on costs and utilities in AD, donepezil treatment in mild-to-moderate AD is 
cost-saving compared to placebo. Treatment delays progression into severe AD, ADL-
dependence and institutionalization and thereby leads to QALY gains.
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OBJECTIVES: Health economic evaluation on the relative value of lamotrigine (LTG) 
and levetiracetame (LEV) in the initial monotherapy of epilepsy METHODS: Paral-
leling an open label, prospective, randomised, multicenter trial including 409 epilepsy 
patients, a health economic evaluation of 81 participants aged q18 years was con-
ducted. Data collection was done by the CRF of the clinical trial and in a series of 
three telephone interviews (baseline and two follow up calls, 3 and 6 months after 
baseline, respectively). The telephone interviews comprised sociodemographics, as well 
as instruments for the evaluation of health-related quality of life, depression and 
resource use). RESULTS: Eighty-one epilepsy patients were included in the economic 
evaluation. Thirty-eight (46.9%) patients were female: 21 (53.8%) in the LTG arm 
and 17 (40.5%) in the LEV arm. The mean duration of the disease was 2.0 o 3.9 
years (LTG) and 2.2 o 6.1 years (LEV). Over the survey period, there was no signiﬁcant 
difference concerning the number of ambulatory consultations (LTG 28 vs. LEV 26) 
or stationary hospital care (LTG 33 vs. LEV 38), though there was a trend for more 
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ambulatory hospital care in the LTG group (LTG 20 vs. LEV 10). No signiﬁcant dif-
ference was found concerning the self-reported health status of the patients (mean EQ 
VAS at follow-up: LTG 75.2 o 18.1 vs. LEV 74.8 o 24.7) nor depression (mean BDI 
sumscore at follow-up: LTG 7.1 o 5.9 vs. LEV 5.9 o 7.5). CONCLUSIONS: No sig-
niﬁcant differences were detected between the two treatment arms concerning ambula-
tory or stationary resource use, self-reported health status or depression. Non-inferiority 
should be proven with an adequate trial design.
PND24
TREATMENT OF ADVANCED PARKINSON’S DISEASE IN THE UNITED 
STATES: A COST-UTILITY MODEL
Tarrants ML1, Groenendaal H2, Armand C3
1Teva Neuroscience, Kansas City, MO, USA, 2Vose Consulting, Boulder, CO, USA, 3H. 
Lundbeck A/S, Paris, France
OBJECTIVES: To assess the cost-utility of rasagiline or entacapone (COMT) as 
adjunctive therapies to levodopa (LD) versus carbidopa/levodopa/entacapone (LCE) 
versus standard LD monotherapy in patients with advanced PD and motor ﬂuctuations 
in the US. As PD progresses, patients and their families experience substantial health 
and economic burdens. Because motor ﬂuctuations are linked to poor quality of life 
and higher health care costs minimizing off-time is an effective strategy for reducing 
costs associated with PD. METHODS: A two-year Markov model was utilized to 
examine the cost-effectiveness of advanced PD treatments. Patients may transition 
therapy every four months. Transition probabilities were obtained from clinical trial 
data. Medical costs, drug costs and utility weights were from published literature. 
RESULTS: Over two years, all therapy options showed greater effectiveness than LD 
alone. Rasagiline and LCE were cost saving from a payer perspective; while COMT 
was cost saving from a societal perspective. Beneﬁts over 2 years were 0.12 additional 
QALYs for rasagiline, COMT and LCE and 5.08 additional months with 25% off-
time for rasagiline and 4.85 for COMT and LCE versus LD alone. CONCLUSIONS: 
From a payer perspective, rasagiline and LCE were dominant therapies to LD mono-
therapy; while COMT was effective at higher cost. With no additional cost over a 2 
year period, rasagiline presents a valuable alternative to COMT, LCE and LD mono-
therapy in the treatment of advanced PD patients. Results from this cost-utility model 
and prior adjunctive clinical data provides ongoing support for rasagiline’s adjunctive 
use in moderate to advanced PD patients with motor ﬂuctuations.
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OBJECTIVES: To assess the cost-effectiveness of memantine, compared with standard 
care, in moderate to severe Alzheimer’s disease (AD) patients. METHODS: A cost-
utility analysis was conducted based on a 3-state Markov model, which simulated 5-
year evolution of pre Full-Time-Care (FTC) patients with and without memantine 
treatment in addition to any background AD therapy, in terms of time-to-FTC, 
Quality-Adjusted-Life-Years (QALYs), and cost. Transition from the pre-FTC to the 
FTC state was modelled using new predictive equations estimating time-to-FTC based 
on clinical assessment of cognition, function, and behaviour. The equations were 
derived from cohort of patients with dementia followed for four years. Treatment 
effect was estimated based on the published meta-analysis of six memantine RCTs. 
Both health utilities (EQ-5D) and resource utilization for the model came from a 
Scandinavian Study of Cost and Quality of Life in AD. Costs were valued from the 
societal perspective, and covered routine patient management, hospitalization, social 
community services, institutionalisation, medications, loss in productivity, and leisure 
time. Memantine cost was accounted for until patients required FTC (conservative). 
Costs and beneﬁts were discounted at an annual rate of 3%. Results were reported in 
Euros (NOK), 2008. The model underwent extensive stochastic and one-way sensitiv-
ity analyses testing the impact of model assumptions and changes in input values for 
treatment effect, health utilities, cost, and discounting rates. RESULTS: Memantine 
was associated with a longer time-to-FTC of 21 days, QALYs gains of 0.02 and a cost 
saving of above a-900 (7,500NOK). Lower costs in memantine group were due to 
prolonged pre-FTC time and offset drug acquisition cost. Memantine was cost-
 effective at a40,000 (300,000NOK) thresholds (72.86%). The sensitivity analyses 
conﬁrmed the robustness of the base-case scenario. CONCLUSIONS: Memantine 
is associated with higher beneﬁts for no additional costs relative to standard care, 
and is a cost-effective treatment.
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OBJECTIVES: Estimate the cost-utility of interferon beta 1B (IFNB-1b) in patients 
with a clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS). 
METHODS: A Markov model was developed using the epidemiology and treatment 
of CIS and MS. The model simulates outcomes over time horizons ranging from 2 
years to lifetime. A hypothetical cohort of 1,000 patients with incident CIS, with initial 
health states deﬁned by Kurtzke’s Expanded Disability Symptom Scale (EDSS), was 
speciﬁed. The cohort was assumed alternatively to be treated with IFNB-1b (250 mg 
eod) following an initial demyelinating event suggestive of MS or not treated until 
conﬁrmation of MS.Data from study BENEFIT was used to model EDSS progression 
over time and transitions from CIS to MS. Exacerbations (relapses) were estimated 
from BENEFIT and published natural history data. Following transition to MS, all 
patients were assumed to be treated with IFNB-1b until EDSS 6.5. Direct and indirect 
medical costs of MS treatment and IFNB-1b were estimated from published literature 
and pricing schedules. Patient utilities were derived from EQ-5D data , supplemented 
by published data deﬁned by EDSS score and relapse occurrence. Mortality was esti-
mated using life tables and EDSS data. Costs (a2008) and outcomes were discounted 
at 3% per annum. Sensitivity analyses were performed on all key model parameters. 
RESULTS: Use of IFNB-1b was associated with slower EDSS progression (longer time 
to MS diagnosis), and reduced relapse burden. In the base case (50-year time horizon), 
ICUR of IFNB-1b versus no treatment was a20,500 / QALY gained using Poser diag-
nostic criteria and dominates using McDonald diagnostic criteria. Findings were sensi-
tive to simulation time horizon, IFNB-1b cost and treatment effect (underlying rate of 
disease progression). CONCLUSIONS: IFNB-1b—treatment of patients with a CIS 
appears to offer reasonable value for money relative to many well accepted health 
care interventions.
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OBJECTIVES: Medicines must be shown to be both clinically and cost-effective 
compared to alternatives in order to be recommended by the National Health Service. 
This study evaluated the cost-effectiveness of pregabalin compared to usual care, in 
patients with refractory neuropathic pain (NeP), i.e., those who had achieved an 
inadequate response to, or were intolerant of, earlier medication including amitripty-
line and gabapentin. METHODS: A Discrete Event Simulation (DES) model was 
constructed to evaluate clinical and economic outcomes of pregabalin versus usual 
care in patients with refractory NeP. An open-label, long term study evaluating pre-
gabalin’s effectiveness in refractory NeP patients over 15 months was used as the 
clinical input to the model. The ‘usual care’ comparator was deﬁned as a group of 
pain medications comprising weak opioids, strong opioids, NSAIDs and/or analgesics. 
New utility data was collected using the EQ-5D via a UK postal survey of hospital 
patients with refractory NeP. This survey also collected costs of other pain medication 
and other health care resources consumed by patients. In each weekly cycle, patients 
accrued costs and beneﬁts associated with their pain score in that cycle, which was 
uniquely deﬁned by the input clinical data. Adverse events and withdrawals, and their 
cost and disutility, were estimated, also based on the input clinical data. Total costs 
and beneﬁts were summed and extrapolated over the ﬁve-year time horizon of the 
model to calculate the ICER. RESULTS: The base case analysis estimated the ICER 
at £10,803/QALY. One-way sensitivity analyses showed that the ICER was stable to 
changes in all input parameters. CONCLUSIONS: This economic evaluation used 
new, real-world utility data in refractory NeP to show that pregabalin provides addi-
tional beneﬁt in patients with refractory NeP at a reasonable cost. To our knowledge, 
this is the ﬁrst economic model to speciﬁcally evaluate a refractory NeP population.
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CARE RESOURCES IN A MULTIPLE SCLEROSIS POPULATION USING 
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OBJECTIVES: To determine if adherence to interferons used to treat patients with 
Multiple Sclerosis (MS) impacts the utilization of health care resources. METHODS: 
A retrospective cohort study design was used. Pharmacy and medical claims data for 
MS patients were extracted for 2006–2008. Adherence was measured using two 
methods for Medication Possession Ratio (MPR), one that incorporates persistence 
and one that does not. Patients were classiﬁed as adherent if they met a standard cut-
off point. The number of hospitalizations, ER visits, and physician ofﬁce visits were 
measured for each patient year. A series of regression models were used to assess the 
impact of adherence on the utilization of health care resources. RESULTS: A total of 
3590 patients were included in the study. Based on the two MPR methods, compliance 
ranged from 77.6% to 89.8%. Patient adherence is a signiﬁcant predictor of whether 
patients have at least 1 ER visit, with those who are adherent having a lower risk of 
ER visits. Patients considered adherent had a signiﬁcantly lower risk of being admitted 
to the hospital than those considered non-adherent. Adherent patients were at higher 
risk of having at least 2 physician ofﬁce visits. The full descriptive and inferential sta-
tistics, and individual year data will be included in the presentation. CONCLUSIONS: 
Interferon therapy is considered an effective treatment for MS patients. This study 
demonstrates that patient adherence to interferon therapy is important in reducing the 
use of expensive, acute health care resources. Patients who were adherent to the 
interferon therapy were less likely to have at least 1 ER visit and at least 1 hospitaliza-
tion, and more likely to have at least 2 physician ofﬁce visits. Reducing health care 
resource use can reduce the total cost of care for MS patients, and as well as increase 
an individual’s long term productivity in society.
